Pakistan Policy Shorts APIs For Pfizer, Abbott, J&J, Group Says
This article was originally published in PharmAsia News
Executive Summary
Pakistan quota delays have led to a shortage of active pharmaceutical ingredients for Pfizer Pakistan, Abbott Laboratories and Johnson & Johnson needed for more than 800 psychotropic drugs, causing a problem beyond the well-being of many patients.